Comparison of biochemical safety between PEG-IFN a-2a and peg-ifn α-2b

Yoshiaki Katano, Takashi Kumada, Isao Nakano, Hidenori Toyoda, Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda, Hidemi Goto

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Background/Aims: Although the efficacy and safety of pegylated-interferon (PEG-IFN) α-2a and PEG-IFN α-2b have been comparatively studied, there are few study results available in which the two PEG-IFN products were strictly compared. To compare the effects of two PEG-IFN products on blood cell profile. Methodology: The time-course change in blood cell counts was compared between chronic hepatitis C patients with genotype lb receiving PEG-IFN α-2a/ribavirin and PEG-IFN α-2b/ribavirin combination therapy. The comparison was made after matching patients from the two groups based on ribavirin apparent clearance (CUB), a surrogate marker of the steady state blood ribavirin level, in order to eliminate the effect of ribavirin. Fifteen pairs of matched patients were selected. Results: The time-course change in hemoglobin did not differ significantly between the two groups. However, significantly greater reductions in both neutrophil and platelet counts were observed with PEG-IFN α-2a compared to PEG-IFN α-2b. A slightly longer period was required with PEG-IFN α-2a than with PEG-IFN α-2b for a reduction in neutrophil or platelet count large enough to necessitate dose reduction. Conclusions: Two types of PEG-IFN products affected the blood cell profile in different manners. Long-term monitoring of laboratory test values is necessary with PEG-IFN α-2a.

Original languageEnglish
Pages (from-to)485-491
Number of pages7
Issue number90
Publication statusPublished - 03-2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Comparison of biochemical safety between PEG-IFN a-2a and peg-ifn α-2b'. Together they form a unique fingerprint.

Cite this